Tim Smith

These data suggest therapeutic modulation of IL-23 inhibitors for psoriasis in those who have shown stability may be a legitimate strategy to ensure efficacy and safety.

These data were the result of a new network meta-analysis looking specifically at children with eczema, highlighting the hierarchy of effectiveness among systemic drugs.

Alpyn’s Investigational New Drug application’s clearance by the FDA for the new Zabalafin Hydrogel for atopic dermatitis follows positive phase 2a clinical findings.

This genome-wide meta-analysis demonstrated that changes in 2 parts of the genome both work to influence patients’ risk of frontal fibrosing alopecia (FFA).

In this feature, 3 experts highlight their own research on new technological advances and their views on the benefits and drawbacks of artificial intelligence in dermatology.

This analysis highlights the major risk factors resulting in limited use of oral JAKi for patients with hidradenitis suppurativa, including smoking, obesity, hypertension, and age.

The February 18, 2025 SOCS News Update highlights SOCS mentorship opportunities as well as the importance of mentors and role models.

The FDA decision to approve the supplemental biologics license application for dupilumab (Dupixent) follows recent pivotal clinical trial data assessing 106 patients.

This analysis highlights the efficacy and safety of abrocitinib among patients with atopic dermatitis in China, as well as the medication’s impact on patients’ blood biomarkers.

These findings from the POETYK-PSO long-term extension trial point to a lack of new safety concerns in the first 5 years of using deucravacitinib for psoriasis.

These data expand upon existing literature on pediatric HS and racial differences among patients based on management, presentation, and severity.

These data highlight deucravacitinib’s impact among patients with psoriasis who are biologic- and apremilast-naive and those with prior histories with these treatments.

In this retrospective analysis, orally administered tofacitinib was shown to be efficacious among younger patients with alopecia areata due to regrowth results.

This approval by the FDA of Evolus’s 2 new hyaluronic acid gels provides an additional set of options for dermatologists in the aesthetic products market.

These data highlight a variety of comorbidities linked to dermatologic diseases in children with obesity, including common comorbidities such as asthma.

This interview highlights the significance of Bruckner’s recent phase 3 data on birch triterpenes as a potential treatment for dystrophic and junctional EB, as well as patients’ unmet needs.

Bruckner discusses her team’s long-term data on the safety and efficacy of birch bark extract, also known as Oleogel-S10, for those with epidermolysis bullosa.

In these new findings, investigators highlight phase 1 research into ritlecitinib for patients aged 6 to 12 years with alopecia areata.

These data point to inaccessibility, distance from providers, and insurance-related barriers as obstacles to mental health improvement among children with atopic dermatitis.

In this retrospective analysis, investigators in Japan highlighted the prevalence and incidence of comorbidities in those with atopic dermatitis, psoriasis, alopecia areata, and vitiligo.

The drug given this designation, known as rezpegaldesleukin, is indicated for adult and pediatric patients aged 12 years and older with atopic dermatitis.

This announcement by INmune Bio, Inc., follows positive findings in the MissionEB clinical trial evaluating CORDStrom for treatment of recessive dystrophic epidermolysis bullosa.

In this study, investigators highlighted factors associated with active hidradenitis suppurativa over the age of 50 such as smoking, male gender, and later onset of disease.

In this analysis, investigators conclude that health-related quality of life and clinical burdens are greater among patients with hidradenitis suppurativa and draining tunnels.

These data suggest that the Family Acceptance and Commitment Therapy-based Eczema Management Program, or FACT-EMP, may be helpful to children with atopic dermatitis.

These data suggest that dupilumab’s drug survival rate at 12 and 24 months is greater than that of upadacitinib and tralokinumab among patients with atopic dermatitis.

In this analysis, investigators concluded that dupilumab may be a viable treatment choice for pregnant or breastfeeding mothers with atopic dermatitis.

This segment of Hebert’s interview features a discussion regarding the safety profile of tapinarof 1% for patients aged 2 years and older with atopic dermatitis.

These data point to milestone event frequency and prevalence by subtype of RDEB, highlighting such events as dysphagia and squamous cell carcinoma.

Adelaide Hebert, MD, discusses the impact of the recent approval for tapinarof cream in the management of atopic dermatitis.